The International Liver Congress 2016 Part I

The International Liver Congress 2016 Part IThe International Liver Congress 2016

The International Liver Congress 2016 (#ILC2016), the annual European Association for the Study of the Liver meeting, is taking place this week in Barcelona, Spain. This blog post is a collection of just some of the topics that have already been discussed at The International Liver Congress 2016.

Topics from The International Liver Congress’s Start

Summary: The all-oral combination of sofosbuvir/velpatasvir with GS-9857, a drug in clinical trials, has been found to be safe and effective on patients who have had treatments fail for them. With the treatment, 99% of trial subjects achieved SVR12.

Summary: A discussion about the potential risks and benefits of treating those with late-stage liver disease. Dr Carlos Fernández Carrillo, Liver Unit of Puerta de Hierro-Majadahonda University Hospital, Spain, stated that, “The results of our study clearly show that those patients suffering from very advanced liver disease may not obtain benefit from these treatments.”

Summary: The study shows that those with hep C who had been previously cured of hepatocellular carcinoma (HCC), the most common form of liver cancer, had a chance of the cancer returning during or after treating their hep C. Researchers say that more study is required.

Summary: Last year the Portuguese government approved treatment for all of their citizens with hep C. 96% of them experienced sustained virologic response.

Abstracts can be found on the ILC 2016 website.

Press Releases by Pharmaceutical Companies from Barcelona

The European Association for the Study of the Liver

Founded in 1966, the European Association for the Study of the Liver is the leading liver association in Europe. Their annual meetings bring together scientific and medical experts from a broad range of fields to discuss their research and findings.